Pfizer inaugurates pay-for-performance in China with money-back Ibrance deal

29th January 2019 Uncategorised 0

Lately, every day seems to bring new talk about “innovative” payment models for expensive drugs in the U.S. and Europe. Now, China is getting enthused, too. Pfizer launched the country’s first pay-for-performance program in cancer with a deal on its blockbuster breast cancer drug Ibrance.

More: Pfizer inaugurates pay-for-performance in China with money-back Ibrance deal
Source: fierce